Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal doxorubicin versus epirubicin in neoadjuvant AC-T for HER2-negative breast cancer
ChiCTR2100054383Phase 4Not yet recruiting
- Sponsor
- The 2nd Affiliated Hospital of Harbin Medical University
- Start
- Dec 2021
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of doxorubicin, epirubicin, cyclophosphamide and docetaxel in breast cancer (2 arms), sponsored by The 2nd Affiliated Hospital of Harbin Medical University. Primary endpoints: Pathologic complete response and Health-related quality of life score. Planned start Dec 2021; status: not yet recruiting.
02
Drugs
doxorubicinepirubicincyclophosphamidedocetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2100054383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100054383.